Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study)

Atherosclerosis

Volumn 150, Issue 2, 2000, Pages 429-436

  Pauciullo, Paolo ^a   Borgnino, Carlo ^b   Paoletti, Rodolfo ^c   Mariani, Mario ^d   Mancini, Mario ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Medical Department   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF PISA   (Italy)

Author keywords

Bezafibrate; Combination therapy; Fluvastatin; Hyperlipidaemia; LDL cholesterol; Triglyceride

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BEZAFIBRATE; CREATINE KINASE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTRACTURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA MULTIFORME; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTERMITTENT CLAUDICATION; LEG CRAMP; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE WEAKNESS; OSTEOARTHRITIS; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SYNCOPE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANTILIPEMIC AGENTS; BEZAFIBRATE; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE V; INDOLES; MALE; MIDDLE AGED; SAFETY; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 0034075647     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(00)00379-8     Document Type: Article

References (37)

1. LaRosa J.C., Hunninghake D., Bush D. et al. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. Circulation. 81:1990;1721-1733.
2. Neaton J.D., Wentworth D.F. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316 099 white men: Multiple Risk Factor Intervention Trial Research Group. Arch. Intern. Med. 152:1992;56-64.
3. Mulddon M.F., Criqui M.H. The emerging role of statins in the prevention of coronary heart disease. Br. Med. J. 315:1997;1554-1555.
4. Plehn J.F., Davis B.R., Sacks F.M. et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the cholesterol and recurrent events (CARE) study. Circulation. 99(2):1999;216-223.
5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study Group. Lancet. 344:1994;1383-1389.
6. Shepherd J., Cobbe S.M., Ford I. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333:1995;1301-1307.
7. Sacks F.M., Pfeffer M.A., Moye L.A. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335:1996;1001-1009.
8. Downs J.R., Clearfield M., Weis S. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. J. Am. Med. Assoc. 279:1998;1615-1622.
9. Sprecher D.L. Triglycerides as a risk factor for coronary artery disease. Am. J. Cardiol. 82(12A):1998;49U-56U.
10. Durrington P.N. Triglycerides are more important in atherosclerosis than epidemiology has suggested. Atherosclerosis. 141:1998;S57-S62.
11. de Faire U., Ericsson C.G., Grip L., Nilsson J., Svane B., Hamsten A. Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Eur. Heart J. 17(Suppl F):1996;37-42.
12. Farmer J.A., Gotto A.M. Jr Currently available hypolipidaemic drugs and future therapeutic developments. Baillieres Clin. Endocrinol. Metab. 9(4):1995;825-847.
13. Knoll R.W., Ciafone R., Galen M. Rhabdomyolysis and renal failure secondary to combination therapy of hyperlipidemia with lovastatin and gemfibozil. Conn. Med. 57(9):1993;593-594.
14. Pierce L.R., Wysowski D.K., Gross T.P. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. J. Am. Med. Assoc. 264(1):1990;71-75.
15. van Puijenbroek E.P., Du Buf-Vereijken P.W., Spooren P.F., van Doormaal J.J. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil. J. Intern. Med. 240(6):1996;403-404.
16. Tal A., Rajeshawari M., Isley W. Rhabdomyolysis associated with simvastatin-gemfibrozil therapy. South. Med. J. 90(5):1997;546-547.
17. Leitersdorf E., Muratti E.N., Eliav O. et al. Efficacy and safety of a combination of fluvastatin-bezafibrate treatment for familial hypercholesterolaemia: comparative efficacy with a fluvastatin-cholestyramine combination. Am. J. Med. 96:1994;401-407.
18. Eliav O., Schurr D., Pfister P., Friedlander Y., Leitersdorf E. High-dose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolaemia. Am. J. Cardiol. 76:1995;76A-79A.
19. Spence J.D., Munoz C.E., Hendricks L., Latchinian L., Khouri H.E. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am. J. Cardiol. 76:1995;80A-83A.
20. Smit J.W.A., Jansen G.H., De Bruin J.W.A., Erkelens D.W. Treatment of combined hyperlidaemia with fluvastatin and gemfibrozil alone and in combination does not induce muscle damage. Am. J. Cardiol. 76:1995;126A-128A.
21. Allain C.C., Poon L.S., Chan C.S., Richmond W., Fu P.C. Enzymatic determination of total serum cholesterol. Clin. Chem. 20(4):1974;470-475.
22. Fossati P., Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin. Chem. 28(10):1982;2077-2080.
23. Vikari J. Precipitation of plasma lipoproteins by PEG-6000 and its evaluation with electrophoresis and ultracentrifugation. Scand. J. Clin. Lab. Invest. 36(3):1976;265-268.
24. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18(6):1972;499-502.
25. Bonetti G., Bosio C., Pagani F., Panteghini M. A new homogeneous assay for the direct measurement of LDL cholesterol in serum. Biochim. Clin. 22:1998;273.
26. Herd J.A., Ballantyne C.M., Farmer J.A. et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am. J. Cardiol. 80:1997;278-286.
27. Serruys P.W., Foley D.P., Jackson G. et al. A randomized placebo controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur. Heart J. 20(1):1999;58-69.
28. Appel S., Dingemanse J. Clinical pharmacokinetics of fluvastatin. Drugs Today. 32(Suppl. A):1996;37-55.
29. Langtry H.D., Markham A. Fluvastatin. A review of its use in lipid disorders. Drugs. 57:1999;583-606.
30. Willis R.A., Folkers K., Tucker J.L., Ye C.Q., Xia L.J., Tamagawa H. Lovastatin decreases coenzyme Q levels in rats. Proc. Natl. Acad. Sci. U.S.A. 87:1988;8928-8930.
31. Mastaglia F.L. Adverse effects of drugs on muscle. Drugs. 24:1982;304-321.
32. Bakker-Arkema R.G., Davidson M.H., Goldstein R.J., Davignon J., Isaacsohn J.L., Weiss S.R., Keison L.M., Brown W.V., Miller V.T., Shurzinske L.J., Black D.M. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. J. Am. Med. Assoc. 275:1996;128-133.
33. Bradley W.A., Gianturco S.H. ApoE is necessary and sufficient for the binding of large triglyceride-rich lipoproteins to the LDL receptor; apoB is unnecessary. J. Lipid Res. 27:1986;40-48.
34. Riegger G., Abletshauser C., Ludwig M., Schwandt P., Widimsky J., Weidinger G., Welzel D. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis. 144:1999;263-270.
35. Hutchesson A.C., Moran A., Jones A.F. Dual bezafibrate-simvastatin therapy for combined hyperlipidaemia. J. Clin. Pharm. Ther. 19(6):1994;387-389.
36. Iliadis E.A., Rosenson R.S. Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia. Clin. Cardiol. 22:1999;25-28.
37. Feher M.D., Foxton J., Banks D., Lant A.F., Wray R. Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease. Br. Heart J. 74(1):1995;14-17.